Payment overview · 2025
General Payments
$221.51
13 reported records · 7 companies
Healthcare provider profile · identity verified
Steven C Mitchell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FAIRFIELD, IL · NPI 1972500460
Verified facts
What the public records show
CMS Open Payments records show Steven C Mitchell, M.D. received $221.51 in general payments during 2025 across 13 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.05 | 20.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.02 | 20.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.89 | 17.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.21 | 14.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.02 | 14.5% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.21 | 6.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.11 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.51 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.02 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.02 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.16 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 81 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 162 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
162 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 951 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 628 | 107 |
| Losartan Potassium | Losartan Potassium | 471 | 108 |
| Hydrochlorothiazide | Hydrochlorothiazide | 429 | 92 |
| Lisinopril | Lisinopril | 429 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 403 | 82 |
| Omeprazole | Omeprazole | 374 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 333 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 68 |
| Furosemide | Furosemide | 309 | 66 |
| Metformin Hcl | Metformin Hcl | 271 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 62 |
| Gabapentin | Gabapentin | 257 | 53 |
| Potassium Chloride | Potassium Chloride | 251 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 59 |
| Famotidine | Famotidine | 234 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 228 | 39 |
| Eliquis | Apixaban | 227 | 37 |
| Simvastatin | Simvastatin | 222 | 49 |
| Warfarin Sodium | Warfarin Sodium | 211 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 183 | 42 |
| Meloxicam | Meloxicam | 169 | 33 |
| Carvedilol | Carvedilol | 166 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 166 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 163 | 32 |
| Jardiance | Empagliflozin | 162 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 162 | 38 |
| Alendronate Sodium | Alendronate Sodium | 147 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 26 |
| Tramadol Hcl | Tramadol Hcl | 140 | 30 |
| Ezetimibe | Ezetimibe | 133 | 27 |
| Mirtazapine | Mirtazapine | 131 | 34 |
| Trazodone Hcl | Trazodone Hcl | 121 | 30 |
| Sertraline Hcl | Sertraline Hcl | 111 | 25 |
| Montelukast Sodium | Montelukast Sodium | 106 | 25 |
| Allopurinol | Allopurinol | 96 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 20 |
| Metformin Hcl Er | Metformin Hcl | 92 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 90 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 26 |
| Donepezil Hcl | Donepezil Hcl | 83 | 19 |
| Trulicity | Dulaglutide | 83 | 15 |
| Ozempic | Semaglutide | 82 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 15 |
| Farxiga | Dapagliflozin Propanediol | 81 | 15 |
| Azithromycin | Azithromycin | 79 | 61 |
| Xarelto | Rivaroxaban | 78 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 18 |
| Celecoxib | Celecoxib | 74 | 12 |
| Memantine Hcl | Memantine Hcl | 73 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 11 |
| Myrbetriq | Mirabegron | 69 | 12 |
| Clonidine Hcl | Clonidine Hcl | 60 | 24 |
| Prednisone | Prednisone | 60 | 38 |
| Lorazepam | Lorazepam | 59 | 23 |
| Entresto | Sacubitril/Valsartan | 58 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 11 |
| Alprazolam | Alprazolam | 54 | suppressed |
| Methylprednisolone | Methylprednisolone | 54 | 51 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | 18 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Novolog Flexpen | Insulin Aspart | 50 | 17 |
| Buspirone Hcl | Buspirone Hcl | 49 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 11 |
| Klor-Con M20 | Potassium Chloride | 47 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | suppressed |
| Atenolol | Atenolol | 45 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 45 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | suppressed |
| Finasteride | Finasteride | 44 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 42 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Glipizide | Glipizide | 40 | 11 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Praluent Pen | Alirocumab | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Sucralfate | Sucralfate | 31 | 11 |
| Glipizide Er | Glipizide | 30 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 15 |
| Fluconazole | Fluconazole | 29 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 15 |
| Ramipril | Ramipril | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.51 · 13 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Cologuard Collection Kit, FARXIGA, INSPIRE, JARDIANCE, LEQVIO, MOUNJARO, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error